InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
63,134.34
(
-0.09%
)
Post# of 253354
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: mcbio post# 116544

Wednesday, 03/16/2011 9:30:59 PM

Wednesday, March 16, 2011 9:30:59 PM

Post# of 253354

Do you see the potential for NKTR118 being a sufficient overhang for PGNX for some time?



Not really. NKTR118 had been known quantity for sometime. Oral Relistor is still ahead of NKTR118 in development. The market is big enough for two oral products. The key to PGNX is to get Relistor subc approved for general population, and Salix does a better job than Wyeth in generating sales. If there weren't oral Relistor, NKTR118 definitely would have pose serious risk on Relistor subc.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up